For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high r ...

Long-term exposure to air pollution poses an increased risk of blood clots in deep veins, which can result in serious ...

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

Wells Fargo has downgraded Editas (EDIT) to equal weight, citing concerns about the potential positioning of reni-cel. Read ...

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

"In this high-risk population with relapsed and refractory disease and extensive prior therapy, pirtobrutinib demonstrated ...

Novel triple-drug therapies have shown promise for various leukemia types, achieving high remission and response rates. Key ...

Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the ...